Company Overview The AI Platform for Precision Medicine May 6, 2025 Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking state ...

BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025.First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss inc ...

合作扩展 - SOPHiA GENETICS与阿斯利康扩大合作 计划2025年将MSK-ACCESS®检测覆盖范围扩展至全球30家临床机构[1] - 此次合作基于2024年10月首次宣布的协议 旨在加速基于SOPHiA DDM™平台的液体活检技术全球部署[1] 技术应用 - MSK-ACCESS®是与纪念斯隆-凯特琳癌症中心联合开发的液体活检应用 通过专有算法分析循环肿瘤DNA(ctDNA) 实现单次抽血检测基因组变异[2] - 该技术适用于传统组织活检不可行场景 包括成本高、周期长、组织不足或侵入性过强等情况 支持实时癌症监测和治疗方案选择[2] 临床验证 - 扩展部署将支持阿斯利康全球真实世界证据计划 验证分散式液体活检在不同医疗体系中的临床影响[3] - 多中心研究中期数据显示 分散式检测的分析性能与纪念斯隆-凯特琳癌症中心原始单点测试结果高度一致[4] 行业影响 - 合作标志着下一代肿瘤诊断技术全球化推广的重要进展 反映液体活检领域发展势头增强[5] - 公司在美国癌症研究协会年会展示数据 证明分散式MSK-ACCESS®解决方案在不同实验室环境下保持准确性和精密度[4][5] 公司背景 - SOPHiA GENETICS为纳斯达克上市公司 专注于通过AI驱动的云原生平台推进数据驱动医疗 覆盖癌症和罕见病领域[7] - SOPHiA DDM™平台可分析复杂基因组和多模态数据 为全球医院、实验室和生物制药机构提供实时洞察[7]